Atropine Mechanism of Action: How It Blocks Acetylcholine

Atropine works by blocking acetylcholine, one of the body’s most widespread chemical messengers, at a specific family of receptors called muscarinic receptors. Because these receptors sit in the heart, eyes, lungs, gut, glands, and brain, a single dose of atropine can change how nearly every major organ system behaves. The drug does not destroy acetylcholine or stop it from being made; it physically occupies the receptor’s binding site so that acetylcholine molecules arriving there have nowhere to land. That competitive relationship between atropine and acetylcholine is the key to understanding everything the drug does, from dilating your pupils to drying your mouth to speeding up your heart.

How Atropine Blocks Acetylcholine

Your nervous system communicates partly through a chemical called acetylcholine, which is released by nerve endings and picked up by receptors on nearby cells. Acetylcholine receptors come in two broad families. Atropine targets the muscarinic family, named after muscarine, a toxin from certain mushrooms that activates those same receptors. There are five known subtypes of muscarinic receptor (labeled M1 through M5), and atropine blocks all of them with roughly equal affinity. This non-selectivity is why the drug has such far-reaching effects across different tissues.

The blocking is competitive, meaning atropine and acetylcholine are essentially fighting over the same parking spot on the receptor. When atropine concentration is high enough, it wins most of those contests, and the receptor stays inactive. When the atropine wears off or is diluted, acetylcholine regains access and normal signaling resumes. Research using mutant receptors has shown that atropine can even act as an “inverse agonist” at certain muscarinic subtypes, meaning it doesn’t just block the receptor but actively pushes its activity below baseline levels, and can trigger the cell to put more receptors on its surface in response to prolonged exposure.¹ For most clinical purposes, though, you can think of atropine simply as a plug that keeps acetylcholine from doing its job.

Atropine itself is a natural compound, the racemic mixture of a molecule called hyoscyamine. It gets its name from Atropa belladonna, the deadly nightshade plant that has been its primary botanical source for centuries.² The “belladonna” part of the plant’s name, meaning “beautiful lady” in Italian, reportedly comes from the historical practice of women dropping the plant extract into their eyes to dilate their pupils for cosmetic effect. That pupil-dilating action remains one of atropine’s best-known clinical uses today.

What Atropine Does to the Heart

Your heart rate is constantly being held in check by the vagus nerve, which releases acetylcholine onto muscarinic receptors in the heart’s pacemaker tissue. This ongoing parasympathetic brake keeps your resting heart rate lower than it would otherwise be. Atropine lifts that brake. By blocking the muscarinic receptors in the heart, it removes the vagal slowing effect and lets the heart rate climb.

The dose matters here in a somewhat counterintuitive way. Very low doses of atropine can actually slow the heart briefly before the expected increase kicks in. Research in healthy volunteers found that low-dose atropine increased the interval between heartbeats by about 9%, shifted heart rate variability patterns toward parasympathetic dominance, and altered sympathetic nerve activity oscillations, all of which are the opposite of what you might expect from a drug famous for speeding the heart up.³ This paradoxical slowing happens because small amounts of atropine can enhance vagal activity centrally in the brainstem before enough drug reaches the heart’s receptors to block them. At higher doses, the peripheral blockade wins out, and heart rate rises as expected. Clinicians account for this by using adequate doses when the goal is to treat a dangerously slow heart rhythm.

Effects on the Eyes

Two muscles inside your eye depend on acetylcholine signaling. The sphincter pupillae constricts your pupil, and the ciliary muscle adjusts the lens for close-up focus. Atropine paralyzes both. The result is a widely dilated pupil (mydriasis) that does not respond to light and an inability to focus on near objects (cycloplegia).⁴ These effects last much longer than those of shorter-acting dilating drops; a single dose of atropine eye drops can blur near vision for a week or more.

Ophthalmologists use atropine’s cycloplegic property to get a true measurement of a child’s refractive error, since the ciliary muscle can mask the actual prescription during an ordinary exam. But the more talked-about ophthalmic use in recent years is myopia control. Low-concentration atropine eye drops, typically 0.01% to 0.05%, have been tested in children to slow the progression of nearsightedness. In a randomized trial of Chinese children, 0.01% atropine drops reduced myopia progression by about a third compared with placebo over one year and slowed the elongation of the eyeball by roughly a fifth.⁵ The exact mechanism behind this myopia-slowing effect is still debated. It may not be entirely about blocking muscarinic receptors on the ciliary muscle; some researchers suspect atropine also acts on receptors in the sclera or retina to influence how the eye grows during childhood.

Drying Secretions and Slowing Airway Clearance

Glands throughout the body, from salivary glands to sweat glands to the mucous-producing cells lining your airways, receive cholinergic signals telling them to secrete. Atropine blocks those signals, which is why dry mouth is one of the most noticeable side effects and why surgeons historically gave atropine before anesthesia to keep the airway dry during intubation.

In the lungs, blocking muscarinic receptors does two things. It relaxes the smooth muscle in the bronchial walls, widening the airways, and it reduces the volume of mucous secretions triggered by cholinergic stimulation. However, atropine also depresses the beating of cilia, the tiny hair-like structures that sweep mucus up and out of the lungs. Studies have shown that atropine slows airway mucociliary clearance, which is a drawback if the patient actually needs to clear mucus effectively.⁶ This side effect helped drive the development of inhaled anticholinergic drugs like ipratropium bromide, which deliver muscarinic blockade directly to the airways without the same degree of ciliary depression or systemic side effects.

Gut and Smooth Muscle

Acetylcholine is the dominant signal telling the smooth muscle of your gastrointestinal tract to contract. By blocking muscarinic receptors in the stomach and intestines, atropine reduces both the frequency and the strength of contractions, slows transit, and can relieve cramping. This is the basis for its historical use in antispasmodic medications and why it appears as an ingredient in combination anti-diarrheal formulations.

The effect extends to other smooth muscle organs as well. Research on surgically created urinary reservoirs found that atropine instilled directly into the reservoir reduced spontaneous contractions, lowered pressure, modestly increased capacity, and decreased the cramping patients experienced when the reservoir was distended.⁷ The bladder’s detrusor muscle, the muscle in bile ducts, and uterine smooth muscle all respond to muscarinic blockade in broadly similar ways: relaxation and reduced motility.

Central Nervous System Effects

Atropine crosses the blood-brain barrier, and muscarinic receptors are abundant throughout the brain. At therapeutic doses, the central effects are modest and often overlooked. At higher doses, the picture changes dramatically. Atropine and its close chemical relative scopolamine are classified as anticholinergic deliriant hallucinogens because of their ability to powerfully disrupt normal brain function when taken in excess.⁸

The hallucinations caused by atropine poisoning are qualitatively different from those caused by psychedelics. People under the influence of large doses often cannot distinguish their visions from reality. They may carry on conversations with people who are not there, attempt to perform routine tasks that make no sense in context, and have little or no memory of the episode afterward. These effects arise from widespread disruption of cholinergic signaling in the cortex and hippocampus, brain regions critical for awareness, attention, and memory formation. It is worth emphasizing that this is toxicity, not a therapeutic effect. No clinical use of atropine aims at its central nervous system actions, and the doses that produce delirium also produce dangerous effects on the heart and body temperature.

The Anticholinergic Toxidrome

When atropine accumulates to supratherapeutic levels, whether from intentional overdose, accidental ingestion, or even systemic absorption from eye drops, it produces a recognizable pattern of poisoning. The classic teaching mnemonic captures it: “dry as a bone, blind as a bat, red as a beet, hot as a hare, mad as a hatter.” Each phrase maps to a specific blocked muscarinic function: absent secretions, dilated pupils, flushed skin from vasodilation, hyperthermia from inability to sweat, and delirium from central receptor blockade.

A case report of a 34-year-old man who ingested 150 mg of atropine illustrates the full toxidrome: he presented with altered mental status, rapid heart rate, dry mucous membranes, flushed skin, and dangerously elevated body temperature.⁹ Even ophthalmic atropine, applied as ordinary eye drops, has caused systemic toxicity severe enough to mimic a stroke in an adolescent patient, a reminder that the drug absorbs readily through mucous membranes.¹⁰

The antidote for atropine poisoning is physostigmine, which works by a completely different strategy than atropine itself. Rather than competing for the receptor, physostigmine blocks the enzyme acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the synapse. With that enzyme inhibited, acetylcholine builds up to concentrations high enough to outcompete atropine for receptor access, effectively reversing the blockade.¹¹

How the Body Handles Atropine

After an intravenous dose, atropine distributes rapidly and widely. Pharmacokinetic studies in healthy people describe a two-phase elimination pattern, with a fast initial distribution phase lasting a couple of minutes and a slower terminal elimination phase with a half-life of roughly two and a half hours. The drug’s volume of distribution is large, around 210 liters, which means it spreads extensively into tissues rather than staying in the bloodstream.¹²

About 57% of the dose is excreted unchanged in the urine, with the kidneys clearing atropine at a rate that suggests active tubular secretion on top of simple filtration. Another 29% shows up in urine as tropine, a breakdown product. The renal clearance of atropine varies with urine flow, meaning hydration status can influence how quickly the drug is eliminated. These numbers matter clinically because patients with impaired kidney function may clear atropine more slowly and be more prone to accumulation and toxicity.¹³

Why Newer Anticholinergics Replaced Atropine in Many Settings

Atropine’s non-selectivity is both its strength and its limitation. Because it blocks all five muscarinic subtypes and crosses into the brain, it tends to produce a broad sweep of side effects whenever it is given systemically. Newer anticholinergic drugs were designed to solve this problem, either by restricting the drug to a specific body compartment or by altering its chemical properties so it does not cross the blood-brain barrier.

Glycopyrrolate is a good example. It is a muscarinic antagonist like atropine, but it carries a permanent positive charge that prevents it from crossing into the central nervous system. In the airways, glycopyrrolate is actually more potent than ipratropium bromide and has a longer duration of action in human airway smooth muscle.¹⁴ Like ipratropium, it binds to M1 through M3 receptors without meaningful subtype selectivity, but its slow dissociation from airway smooth muscle receptors gives it staying power in the lungs.

The clinical difference shows up clearly in side effects. A study comparing inhaled atropine and glycopyrrolate in asthma found that dry mouth, flushing, and resting tachycardia were prominent with atropine, while glycopyrrolate produced side effects no different from placebo.¹⁵ Ipratropium bromide similarly avoids the mucociliary depression that atropine causes, making it safer for long-term use in patients with chronic obstructive lung disease who need ongoing bronchodilation without compromised mucus clearance.¹⁶

Researchers have also explored building hybrid molecules that combine atropine’s orthosteric binding with an allosteric component to create subtype-selective antagonists. By attaching additional chemical groups to the basic atropine scaffold and connecting them through a linker, scientists have created compounds whose spatial orientation inside the receptor determines whether they preferentially block M2 or M5 subtypes.¹⁷ This line of work is still largely experimental, but it illustrates the direction the field is heading: using atropine as a starting point to design drugs that hit only the muscarinic subtypes responsible for the desired effect.

Rabbits and the Atropinesterase Puzzle

One of the more curious footnotes in atropine pharmacology involves rabbits. Some rabbits possess an enzyme in their blood plasma, called atropinesterase, that can break down large quantities of atropine. This enzyme appears to be partly enantiomer-specific, preferring one mirror-image form of the molecule. Not all rabbits have the same level of this enzyme, and the trait varies substantially between individual animals.¹⁸

Plasma from other species, including humans, does show some capacity to hydrolyze atropine, but at rates that barely exceed spontaneous chemical breakdown. It remains unclear whether this trace activity reflects a very low level of a dedicated atropinesterase or a different hydrolytic enzyme acting on atropine incidentally. The practical takeaway is that rabbits make poor models for predicting atropine dosing in humans because they clear the drug by a route that people essentially lack. Veterinarians working with rabbits also need to be aware that standard atropine doses used in other species may be insufficient because some individual rabbits will metabolize the drug almost as fast as it is administered.